Stock 0512 CHINA GRAND PHA.AND HEALTHCARE HLD. LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

China Grand Pha.and Healthcare Hld. Ltd. Stock Hong Kong S.E.

Equities

0512

BMG210A71198

Pharmaceuticals

Financials

Sales 2023 10.53B 1.34B Sales 2024 * 12.06B 1.54B Capitalization 13.76B 1.76B
Net income 2023 1.88B 240M Net income 2024 * 2.44B 312M EV / Sales 2023 1.37 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 1.14 x
P/E ratio 2023
7.63 x
P/E ratio 2024 *
5.7 x
Employees -
Yield 2023
6.36%
Yield 2024 *
3.31%
Free-Float 28.39%
More Fundamentals * Assessed data

Chart China Grand Pha.and Healthcare Hld. Ltd.

Dynamic Chart

Latest news about China Grand Pha.and Healthcare Hld. Ltd.

Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc CI
Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug MT
Grand Pharmaceutical Group Limited Announces That ITM-11, A Global Innovative Radionuclide-Drug Conjugate of the Group for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors CI
Grand Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Grand Pharmaceutical Group's Partner Gets FDA Approval for Eye Medication MT
Grand Pharmaceutical Group's Children's Myopia Drug Approved for Phase I Trial MT
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884 CI
Grand Pharmaceutical's New Drug Application for Antihistamine Nasal Spray Accepted in China MT
Grand Pharmaceutical Unit's Investigational New Drug Application for Tumor Vaccine Gets Nod from Chinese Regulator MT
Grand Pharmaceutical's Unit Further Acquires Stake in Chongqing Duoputai Pharmaceutical for 442.26 Million Yuan MT
Grand Pharmaceutical Secures Chinese Approval for Phase 1 Trial of Eye Drops MT
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA CI
Grand Pharmaceutical's Unit Acquires Controlling Stake in Tianjin Tanabe Seiyaku for HK$400 Million MT
Grand Pharmaceutical's Subsidiaries to Resell Sirtex's Products for 166.5 Million Yuan MT
Grand Pharmaceutical Buys 27% of Duoputai Pharmaceutical Technology for 189.54 Million Yuan MT
More news

Latest transcript on China Grand Pha.and Healthcare Hld. Ltd.

Logo China Grand Pha.and Healthcare Hld. Ltd.
Grand Pharmaceutical Group Limited, Telix Pharmaceuticals Limited - Special Call
More transcripts

Press releases China Grand Pha.and Healthcare Hld. Ltd.

China Monthly Antitrust Update - June 2023 AQ
Telix-Grand Pharma Investor Webcast AQ
VOLUNTARY ANNOUNCEMENT: SIR-SPHERES Y-90 RESIN MICROSPHERES DOSED THE FIRST HCC PATIENT OF THE U.S. CLINICAL TRIAL PU
China Grand Pharmaceutical and Healthcare : Proxy form for the annual general meeting to be held on 1 June 2021 or any adjournment thereof PU
China Grand Pharmaceutical and Healthcare : GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES; RE-ELECTION OF RETIRING DIRECTORS AND APPOINTMENT OF DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING PU
More press releases

Managers and Directors - China Grand Pha.and Healthcare Hld. Ltd.

Managers TitleAgeSince
Chao Zhou CEO
 Chief Executive Officer 34 19-03-31
Tin Chung Foo SEC
 Corporate Secretary 56 11-08-31
Members of the board TitleAgeSince
Tosi Wan So BRD
 Director/Board Member 61 05-03-20
Ye Bi Hu BRD
 Director/Board Member 60 18-12-30
Geng Pei BRD
 Director/Board Member 64 11-05-11
More insiders

Company Profile

Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a Hong Kong-based investment holding company principally engaged in the manufacturing and sales of pharmaceutical preparations and medical devices. The Company is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.
Sector
Pharmaceuticals
Calendar
2024-08-06 - Q2 2024 Earnings Release (Projected)
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.97% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.18% 550B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.02% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.85% 317B
ABBVIE INC. Stock AbbVie Inc.
+6.25% 292B
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.17% 211B
NOVARTIS AG Stock Novartis AG
-0.29% 203B
ROCHE HOLDING AG Stock Roche Holding AG
-10.10% 194B
PFIZER, INC. Stock Pfizer, Inc.
-11.81% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 512 Stock
  4. 0512 Stock